Ensysce Biosciences to Showcase Innovative Pain Relief Solutions at the 37th Annual ROTH Conference
San Diego, CA – March 5, 2025
Ensysce Biosciences, Inc., a pioneering clinical-stage pharmaceutical company, has announced its participation in the esteemed 37th Annual ROTH Conference. Scheduled to take place from March 16th to 18th at the picturesque Laguna Cliffs Marriott Resort in Dana Point, CA, this prestigious event is an excellent platform for Ensysce to engage with investors and showcase its groundbreaking solutions for severe pain relief, all while minimizing the risk of opioid abuse and overdose.
A Triumvirate of Ensysce’s Leaders to Attend
Joining the ranks of this year’s conference are Ensysce’s Chief Executive Officer, Dr. Lynn Kirkpatrick; Chief Financial Officer, Dave Humphrey; and Chief Commercial Officer, Geoff Birkett. These seasoned industry professionals will be available for one-on-one meetings with interested investors, providing invaluable insights into the company’s mission, progress, and future plans.
Ensysce’s Innovative Approach to Pain Relief
Ensysce’s commitment to addressing severe pain without relying on opioids has garnered widespread attention. The company’s cutting-edge research and development efforts focus on creating alternative pain relief solutions that offer significant benefits over traditional opioid-based treatments. By harnessing the power of advanced science and technology, Ensysce aims to revolutionize the way we manage pain, ultimately enhancing patients’ quality of life and contributing to the global fight against the opioid epidemic.
Impact on Individuals: Hope for Pain Sufferers
For individuals grappling with chronic pain, the potential impact of Ensysce’s innovative solutions is immense. Opioid-based painkillers, while effective in managing pain, come with a host of risks, including addiction, overdose, and adverse side effects. Ensysce’s alternative pain relief therapies could offer a safer, more effective alternative, providing relief without the danger of opioid abuse.
Impact on the World: A Step Toward a Safer Future
The opioid epidemic has been a global concern for years, with millions of lives affected and billions of dollars spent on healthcare and related costs. Ensysce’s participation in the ROTH Conference marks a significant step forward in the fight against this crisis. By presenting its innovative pain relief solutions to investors and industry experts, the company is poised to attract the resources and support needed to bring these groundbreaking therapies to market. Ultimately, this could lead to a world where pain relief is safer, more effective, and free from the risks associated with opioids.
Conclusion: A Bright Future for Pain Relief
As the world continues to grapple with the opioid epidemic, Ensysce Biosciences’ innovative approach to pain relief offers a glimmer of hope. With its participation in the 37th Annual ROTH Conference, the company is taking a crucial step toward securing the funding and support needed to bring its groundbreaking therapies to market. For pain sufferers and the global community, this is a future worth looking forward to.
- Ensysce Biosciences to attend the 37th Annual ROTH Conference from March 16th to 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.
- CEO Dr. Lynn Kirkpatrick, CFO Dave Humphrey, and CCO Geoff Birkett to be available for one-on-one meetings with investors.
- Company focuses on developing innovative pain relief solutions that reduce the potential for opioid abuse and overdose.
- Impact on individuals: safer, more effective alternative to opioid-based painkillers.
- Impact on the world: a step toward a future where pain relief is free from the risks associated with opioids.
